{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T08:48:50Z","timestamp":1777625330674,"version":"3.51.4"},"reference-count":33,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2019,12,1]],"date-time":"2019-12-01T00:00:00Z","timestamp":1575158400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,12,1]],"date-time":"2019-12-01T00:00:00Z","timestamp":1575158400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100007859","name":"University of Kansas","doi-asserted-by":"publisher","award":["2302324"],"award-info":[{"award-number":["2302324"]}],"id":[{"id":"10.13039\/100007859","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jpharmsci.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Pharmaceutical Sciences"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1016\/j.xphs.2019.09.015","type":"journal-article","created":{"date-parts":[[2019,9,20]],"date-time":"2019-09-20T18:36:02Z","timestamp":1569004562000},"page":"3870-3878","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"title":["Improving Eflornithine Oral Bioavailability and Brain Uptake by Modulating Intercellular Junctions With an E-cadherin Peptide"],"prefix":"10.1016","volume":"108","author":[{"given":"Sihyung","family":"Yang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yao","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mei","family":"Feng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Larry","family":"Rodriguez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Judy Qiju","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael Zhuo","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.xphs.2019.09.015_bib1","doi-asserted-by":"crossref","first-page":"e1007","DOI":"10.1371\/journal.pntd.0001007","article-title":"The human African trypanosomiasis control and surveillance programme of the World Health Organization 2000-2009: the way forward","volume":"5","author":"Simarro","year":"2011","journal-title":"PLoS Negl Trop Dis"},{"issue":"9709","key":"10.1016\/j.xphs.2019.09.015_bib2","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/S0140-6736(09)60829-1","article-title":"Human African trypanosomiasis","volume":"375","author":"Brun","year":"2010","journal-title":"Lancet"},{"issue":"11","key":"10.1016\/j.xphs.2019.09.015_bib3","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1016\/j.tig.2006.08.003","article-title":"Switching trypanosome coats: what's in the wardrobe?","volume":"22","author":"Taylor","year":"2006","journal-title":"Trends Genet"},{"issue":"4","key":"10.1016\/j.xphs.2019.09.015_bib4","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1172\/JCI33945","article-title":"Kinetoplastids: related protozoan pathogens, different diseases","volume":"118","author":"Stuart","year":"2008","journal-title":"J\u00a0Clin Invest"},{"issue":"5","key":"10.1016\/j.xphs.2019.09.015_bib5","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1086\/432576","article-title":"Eflornithine is safer than melarsoprol for the treatment of second-stage Trypanosoma brucei gambiense human African trypanosomiasis","volume":"41","author":"Chappuis","year":"2005","journal-title":"Clin Infect Dis"},{"issue":"2","key":"10.1016\/j.xphs.2019.09.015_bib6","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1038\/clpt.1981.150","article-title":"Kinetics of alpha-difluoromethylornithine: an irreversible inhibitor of ornithine decarboxylase","volume":"30","author":"Haegele","year":"1981","journal-title":"Clin Pharmacol Ther"},{"issue":"4","key":"10.1016\/j.xphs.2019.09.015_bib7","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1111\/j.1471-4159.2008.05706.x","article-title":"The blood-brain barrier significantly limits eflornithine entry into Trypanosoma brucei brucei infected mouse brain","volume":"107","author":"Sanderson","year":"2008","journal-title":"J\u00a0Neurochem"},{"issue":"4","key":"10.1016\/j.xphs.2019.09.015_bib8","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1007\/s00228-004-0759-7","article-title":"The pharmacokinetics of eflornithine (alpha-difluoromethylornithine) in patients with late-stage T.b. gambiense sleeping sickness","volume":"60","author":"Na-Bangchang","year":"2004","journal-title":"Eur J Clin Pharmacol"},{"issue":"9683","key":"10.1016\/j.xphs.2019.09.015_bib9","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/S0140-6736(09)61117-X","article-title":"Nifurtimox-eflornithine combination therapy for second-stage African Trypanosoma brucei gambiense trypanosomiasis: a multicentre, randomised, phase III, non-inferiority trial","volume":"374","author":"Priotto","year":"2009","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.xphs.2019.09.015_bib10","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1016\/j.bbamem.2008.09.016","article-title":"Potential use of tight junction modulators to reversibly open membranous barriers and improve drug delivery","volume":"1788","author":"Deli","year":"2009","journal-title":"Biochim Biophys Acta"},{"issue":"5","key":"10.1016\/j.xphs.2019.09.015_bib11","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1517\/17425240902902315","article-title":"Tight junction modulator and drug delivery","volume":"6","author":"Matsuhisa","year":"2009","journal-title":"Expert Opin Drug Deliv"},{"issue":"10","key":"10.1016\/j.xphs.2019.09.015_bib12","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.4155\/tde.14.67","article-title":"Pathways and progress in improving drug delivery through the intestinal mucosa and blood-brain barriers","volume":"5","author":"Laksitorini","year":"2014","journal-title":"Ther Deliv"},{"issue":"8","key":"10.1016\/j.xphs.2019.09.015_bib13","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1023\/A:1019850226631","article-title":"Increasing paracellular porosity by E-cadherin peptides: discovery of bulge and groove regions in the EC1-domain of E-cadherin","volume":"19","author":"Sinaga","year":"2002","journal-title":"Pharm Res"},{"issue":"1","key":"10.1016\/j.xphs.2019.09.015_bib14","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1021\/mp100293m","article-title":"Enhancement of drug absorption through the blood-brain barrier and inhibition of intercellular tight junction resealing by E-cadherin peptides","volume":"8","author":"Kiptoo","year":"2011","journal-title":"Mol Pharm"},{"issue":"4","key":"10.1016\/j.xphs.2019.09.015_bib15","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1023\/A:1011094025008","article-title":"Improving the selectivity of HAV-peptides in modulating E-cadherin-E-cadherin interactions in the intercellular junction of MDCK cell monolayers","volume":"18","author":"Makagiansar","year":"2001","journal-title":"Pharm Res"},{"issue":"3","key":"10.1016\/j.xphs.2019.09.015_bib16","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1021\/mp400624v","article-title":"Modulation of blood-brain barrier permeability in mice using synthetic E-cadherin peptide","volume":"11","author":"On","year":"2014","journal-title":"Mol Pharm"},{"issue":"3","key":"10.1016\/j.xphs.2019.09.015_bib17","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1002\/jps.24309","article-title":"Modulation of intercellular junctions by cyclic-ADT peptides as a method to reversibly increase blood-brain barrier permeability","volume":"104","author":"Laksitorini","year":"2015","journal-title":"J\u00a0Pharm Sci"},{"issue":"5000","key":"10.1016\/j.xphs.2019.09.015_bib18","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1126\/science.2006419","article-title":"Cadherin cell adhesion receptors as a morphogenetic regulator","volume":"251","author":"Takeichi","year":"1991","journal-title":"Science"},{"issue":"8","key":"10.1016\/j.xphs.2019.09.015_bib19","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1038\/nrm1699","article-title":"Regulation of cadherin-mediated adhesion in morphogenesis","volume":"6","author":"Gumbiner","year":"2005","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"1","key":"10.1016\/j.xphs.2019.09.015_bib20","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1080\/07391102.2015.1133321","article-title":"Probing the interaction between cHAVc3 peptide and the EC1 domain of E-cadherin using NMR and molecular dynamics simulations","volume":"35","author":"Alaofi","year":"2017","journal-title":"J\u00a0Biomol Struct Dyn"},{"issue":"2","key":"10.1016\/j.xphs.2019.09.015_bib21","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1016\/S0022-3549(15)00188-4","article-title":"Comparison of linear and cyclic His-Ala-Val peptides in modulating the blood-brain barrier permeability: impact on delivery of molecules to the brain","volume":"105","author":"Alaofi","year":"2016","journal-title":"J\u00a0Pharm Sci"},{"issue":"7","key":"10.1016\/j.xphs.2019.09.015_bib22","doi-asserted-by":"crossref","first-page":"4064","DOI":"10.1128\/AAC.02605-14","article-title":"Pharmacokinetic comparison to determine the mechanisms underlying the differential efficacies of cationic diamidines against first- and second-stage human African trypanosomiasis","volume":"58","author":"Yang","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.xphs.2019.09.015_bib23","series-title":"Guidance for Industry: In Vitro Metabolism- and Transporter-Mediated Drug-Drug Interaction Studies","year":"2017"},{"issue":"1","key":"10.1016\/j.xphs.2019.09.015_bib24","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1021\/js9803205","article-title":"MDCK (Madin-Darby canine kidney) cells: a tool for membrane permeability screening","volume":"88","author":"Irvine","year":"1999","journal-title":"J\u00a0Pharm Sci"},{"issue":"1","key":"10.1016\/j.xphs.2019.09.015_bib25","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/S0022-3565(24)37802-4","article-title":"Absorption enhancement, structural changes in tight junctions and cytotoxicity caused by palmitoyl carnitine in Caco-2 and IEC-18 cells","volume":"287","author":"Duizer","year":"1998","journal-title":"J\u00a0Pharmacol Exp Ther"},{"issue":"6","key":"10.1016\/j.xphs.2019.09.015_bib26","doi-asserted-by":"crossref","first-page":"2507","DOI":"10.1128\/AAC.00250-10","article-title":"Novel arylimidamides for treatment of visceral leishmaniasis","volume":"54","author":"Wang","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"issue":"1","key":"10.1016\/j.xphs.2019.09.015_bib27","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1211\/jpp.60.1.0008","article-title":"Measurements of rat and mouse gastrointestinal pH, fluid and lymphoid tissue, and implications for in-vivo experiments","volume":"60","author":"McConnell","year":"2008","journal-title":"J\u00a0Pharm Pharmacol"},{"issue":"6","key":"10.1016\/j.xphs.2019.09.015_bib28","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1002\/bmc.3374","article-title":"A\u00a0simple and sensitive assay for eflornithine quantification in rat brain using pre-column derivatization and UPLC-MS\/MS detection","volume":"29","author":"Yang","year":"2015","journal-title":"Biomed Chromatogr"},{"issue":"4","key":"10.1016\/j.xphs.2019.09.015_bib29","first-page":"540","article-title":"The origins of the circumventricular organs","volume":"232","author":"Kiecker","year":"2018","journal-title":"J\u00a0Anat"},{"issue":"7","key":"10.1016\/j.xphs.2019.09.015_bib30","doi-asserted-by":"crossref","first-page":"603","DOI":"10.2174\/138920010792927325","article-title":"Structure and function of the human breast cancer resistance protein (BCRP\/ABCG2)","volume":"11","author":"Ni","year":"2010","journal-title":"Curr Drug Metab"},{"issue":"3","key":"10.1016\/j.xphs.2019.09.015_bib31","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1517\/17425255.2.3.351","article-title":"Structure and function of the MRP2 (ABCC2) protein and its role in drug disposition","volume":"2","author":"Jedlitschky","year":"2006","journal-title":"Expert Opin Drug Metab Toxicol"},{"issue":"4","key":"10.1016\/j.xphs.2019.09.015_bib32","doi-asserted-by":"crossref","first-page":"406","DOI":"10.3109\/03602532.2015.1105253","article-title":"MRP1 and its role in anticancer drug resistance","volume":"47","author":"Lu","year":"2015","journal-title":"Drug Metab Rev"},{"issue":"11","key":"10.1016\/j.xphs.2019.09.015_bib33","doi-asserted-by":"crossref","first-page":"e1001204","DOI":"10.1371\/journal.ppat.1001204","article-title":"A\u00a0molecular mechanism for eflornithine resistance in African trypanosomes","volume":"6","author":"Vincent","year":"2010","journal-title":"PLoS Pathog"}],"container-title":["Journal of Pharmaceutical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S002235491930588X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S002235491930588X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T00:00:18Z","timestamp":1777420818000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S002235491930588X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12]]},"references-count":33,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["S002235491930588X"],"URL":"https:\/\/doi.org\/10.1016\/j.xphs.2019.09.015","relation":{},"ISSN":["0022-3549"],"issn-type":[{"value":"0022-3549","type":"print"}],"subject":[],"published":{"date-parts":[[2019,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Improving Eflornithine Oral Bioavailability and Brain Uptake by Modulating Intercellular Junctions With an E-cadherin Peptide","name":"articletitle","label":"Article Title"},{"value":"Journal of Pharmaceutical Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.xphs.2019.09.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 American Pharmacists Association\u00ae. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}